4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly

The obesity market has garnered much interest lately, ever since Novo Nordisk (NVO) received FDA approval for its obesity drug Wegovy in 2021. It was only after a couple of years that the market gained a second entrant – Eli Lilly’s (LLY) Zepbound, which received FDA approval last year in November.Lilly and Novo have been registering top- and bottom-line growth, owing to the vastness of the total market size for obesity. The companies even achieved a market cap north of $500 billion. However, these firms ha ...